Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia 6Leukemia, Hairy Cell 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, Non-Hodgkin 3Recurrence 2Lymphoma 2Leukemia, Lymphocytic, Chronic, B-Cell 2Neoplasms 1Leukemia, Prolymphocytic 1Leukemia, B-Cell 1Cerebral Palsy 1

Interventions

Cyclophosphamide 17ofatumumab 14fludarabine 11Rituximab 11ibrutinib 10fludarabine phosphate 9acalabrutinib 7Lenalidomide 6Bendamustine Hydrochloride 6venetoclax 5obinutuzumab 5Vincristine 4Mesna 4Melphalan 4Immunotherapy, Adoptive 4pirtobrutinib 3Whole-Body Irradiation 3Mycophenolic Acid 3Chlorambucil 3Bortezomib 3Alemtuzumab 3spebrutinib 2navitoclax 2idelalisib 2Tacrolimus 2Tablets 2Stem Cell Transplantation 2Peripheral Blood Stem Cell Transplantation 2Patient Reported Outcome Measures 2KW-2478 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, B-Cell × immunotoxin HA22 × Clear all
NCT02227108 2017-04-06

Study in Pediatrics With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma

MedImmune LLC

Phase 2 Terminated
37 enrolled 24 charts
LymphoidOther hematologic neoplasm

Neoplasms, Leukemia, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡